# Daniela Begolo

> Daniela Begolo is a Series B investor at EQT Life Sciences backing Medical and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners)
- Total investments: 3
- Last investment: Jan 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/danielabegolo

Daniela Begolo is a Series B investor at EQT Life Sciences focused on Medical and Therapeutics. Daniela Begolo is the Board Member of Mosanna Therapeutics and Managing Director of EQT Life Sciences. She attended Heidelberg University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Series A | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Spain | 1 | 33% |
| Switzerland | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kinaset Therapeutics | Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M | Series B | Jan 10, 2026 |  |
| Splice Bio | Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M | Series B | Jun 11, 2025 |  |
| Mosanna Therapeutics | Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach. | $80M | Series A | Jun 09, 2025 |  |

3 of 3 investments shown.

## Co-investors
- [Forge Life Science Partners](https://shizune.co/investors/profile/forge-life-science-partners) — VC Fund, 2 deals together
- [Norwest](https://shizune.co/investors/profile/norwest-venture-partners) — VC Fund, 2 deals together
- [Asabys Partners](https://shizune.co/investors/profile/asabys-partners) — VC Fund, 1 deal together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 1 deal together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 1 deal together
- [Forbion Capital Partners](https://shizune.co/investors/profile/forbion-capital-partners) — VC Fund, 1 deal together

## About EQT Life Sciences

VC Fund · Amsterdam, The Netherlands

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

5 contacts available at EQT Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Christoph Broja | Partner | https://shizune.co/investors/profile/christoph-broja-c9a3 |
| Fouad Azzam | General Partner | https://shizune.co/investors/profile/fouad-azzam |
| Joachim Rothe | General Partner | https://shizune.co/investors/profile/joachim-rothe |
| Daniela Begolo | Managing Director | https://shizune.co/investors/profile/daniela-begolo |
| Ellen Cordo | Chief Finance | https://shizune.co/investors/profile/ellen-cordo |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Daniela Begolo invest in?

Daniela Begolo invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 3 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Daniela Begolo last invest?

The most recent investment recorded for Daniela Begolo closed in Jan 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co